Preferred Label : Sitravatinib;
NCIt synonyms : 1,1-Cyclopropanedicarboxamide, N-(3-Fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)-;
NCIt definition : An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic
activity. Upon administration, sitravatinib binds to and inhibits the activity of
several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein
kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor
receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor
2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1),
2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor
receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related
kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases.
This may result in both the inhibition of signal transduction pathways mediated by
these RTKs and the reduction of tumor cell proliferation in cancer cell types that
overexpress these RTKs.;
UNII : CWG62Q1VTB;
InChIKey : WLAVZAAODLTUSW-UHFFFAOYSA-N;
CAS number : 1123837-84-2;
Molecule name : MGCD516;
NCI Metathesaurus CUI : CL474129;
Origin ID : C117734;
UMLS CUI : C4309514;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
